ACAD ACADIA PHARMACEUTICALS INCcompanySEC Filings & Insider Trading Activity 2026
Latest ACADIA PHARMACEUTICALS INC (ACAD) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on May 1, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ACADIA PHARMACEUTICALS INC (ACAD) (SEC CIK 1070494), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: biopharmaceutical focus on neurological and rare diseases with $1.07B net sales from NUPLAZID and DAYBUE in 2025, up from $958M in 2024
- • New product launch: DAYBUE STIX powder formulation introduced in Q1 2026 for Rett syndrome, offering dosing flexibility and improved patient experience
Risk Factors
- • Cybersecurity incident escalation to audit committee requiring coordination among CIDO, Chief Legal Officer, and Senior VP of Finance
- • New CIDO hired August 2025 tasked with integrating cybersecurity risk into overall risk strategy
Management Discussion & Analysis
- • Revenue $1,071.5M in 2025 vs $957.8M in 2024, driven by NUPLAZID and DAYBUE sales, up $113.7M YoY
- • Operating loss driven by R&D expenses $328.8M in 2025 vs $303.2M in 2024; gross-to-net adjustments reduced net sales by $20.1M from Medicare rebate revision
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New regulatory risk: January 2025 EU HTA Regulation No 2021/2282 requires joint clinical assessments impacting trofinetide pricing and reimbursement
- • Updated product acceptance risk: DAYBUE approved October 2024 in Canada; reliance on patient adherence and physician prescribing for Rett syndrome sales
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Jonathan M. Poole appointed to ACAD Board effective March 3, 2026 as Class II director; term expires at 2027 Annual Meeting
- • Annual cash compensation: $50,000 board retainer + $12,500 Audit Committee retainer, prorated
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced Feb 25, 2026; details in Exhibit 99.1
- • Full results (revenue, earnings, guidance) contained in press release — key figures require review of Exhibit 99.1
Annual Reports Archive10-K
AI-powered analysis of ACADIA PHARMACEUTICALS INC (ACAD) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of ACADIA PHARMACEUTICALS INC (ACAD) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ACADIA PHARMACEUTICALS INC (ACAD) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $517.2M | $726.4M | $957.8M | $1.1B |
| Gross Profit | $507.1M | $684.8M | — | — |
| Operating Income | — | -$73.4M | $230.8M | $104.8M |
| Net Income | -$216.0M | -$61.3M | $226.5M | $391.0M |
| Gross Margin | 98.0% | 94.3% | — | — |
| Op. Margin | — | -10.1% | 24.1% | 9.8% |
| Net Margin | -41.8% | -8.4% | 23.6% | 36.5% |
| Balance Sheet | ||||
| Total Assets | — | $749.0M | $1.2B | $1.6B |
| Equity | $400.4M | $431.8M | $732.8M | $1.2B |
| ROE | -53.9% | -14.2% | 30.9% | 31.9% |
Source: XBRL financial data from ACADIA PHARMACEUTICALS INC (ACAD) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | May 1, 2026 | — | — | — |
8-K | Mar 5, 2026 | — | Analysis | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 25, 2026 | — | Analysis | — |
8-K | Jan 13, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Mar 1, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Feb 25, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest ACAD SEC filings in 2026?
ACADIA PHARMACEUTICALS INC (ACAD) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on May 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ACAD file its most recent 10-K annual report?
ACADIA PHARMACEUTICALS INC (ACAD) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ACAD 10-Q quarterly reports?
ACADIA PHARMACEUTICALS INC (ACAD)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every ACAD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ACAD filed recently?
ACADIA PHARMACEUTICALS INC (ACAD)'s most recent 8-K was filed on May 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ACAD insider trading activity (Form 4)?
SignalX aggregates every ACAD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ACAD file with the SEC?
ACADIA PHARMACEUTICALS INC (ACAD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ACAD filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ACADIA PHARMACEUTICALS INC (ACAD).
What is ACAD's SEC CIK number?
ACADIA PHARMACEUTICALS INC (ACAD)'s SEC CIK (Central Index Key) number is 1070494. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1070494 to look up all ACAD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ACAD return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ACADIA PHARMACEUTICALS INC (ACAD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ACADIA PHARMACEUTICALS INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 69+ filings.